Source: HINATURE INC.

Source

SINGAPORE, Feb. 28, 2026 /PRNewswire/ — Orange Clove has been recognised as Singapore’s No. 1 Corporate Caterer^[1] by Euromonitor International, based on 2024 customer value sales, having served over 830,000 guests that same year. The company has also received the EXSA (Excellent Service Award) 2025, a testament to its commitment to exceptional service and operational excellence in corporate catering. Together, these accolades highlight Orange Clove’s position as a leader in Singapore’s highly competitive catering industry.

These latest wins add to a long track record of industry recognition. Over the years, the company has been honoured with numerous business and brand awards, including the Promising SME 500 and SME One Asia Awards (2013), and multiple accolades under the Singapore Prestige Brand Award (SPBA), such as Overall Winner – Promising Brands (2014), Overall Winner – Established Brands (2015), and induction into the SPBA Hall of Fame (2015).

Culinary excellence has also been celebrated with honours including the Epicurean Star Award (Best Caterer, 2014) and World Gourmet Summit’s Outstanding Caterer of the Year (2015). Service excellence has been recognised through HRM Asia Readers’ Choice (2014 & 2015), ExpatLiving Readers’ Choice Awards (2019, 2020 & 2022), and The Straits Times Singapore’s Best Customer Service (2023/24 & 2024/25). In recent years, lifestyle and community platforms have also celebrated Orange Clove, including Honeycombers Readers’ Choice Gold (2023), Tatler – Best of Singapore (2020 & 2021), National Arts Council – Patron of the Arts Awards (2023, 2024 & 2025) and Singapore Food Agency – Farm-to-Table Recognition Programme.

About Orange Clove

Founded in 2008, Orange Clove has grown from a buffet provider into a full-service corporate catering partner for multinational corporations, government agencies, and small-to-medium enterprises. Its offerings span signature buffets, bento sets, seminar packages, canapés, live culinary stations, and more.

Key to Success

Industry observers note that Orange Clove’s success is driven by culinary innovation, operational precision, and a focus on customer experience. Over the years, the company has collaborated with leading chefs and industry partners to introduce distinctive menu items, creative dining concepts, and imaginative event setups.

Milestones in Culinary and Event Innovation:

2015 — Moving Connoisseur: A portable conveyor belt inspired by sushi trains, bringing movement and interactivity to corporate dining.
2016 — Aurora Dessert Bar: The first of its kind in catering, transforming dessert tables into five-star showcases.
2017 — Chef Collaboration with Chef Eric Low: A festive partnership that brought fresh creativity to Christmas menus.
2019 — Collaboration with the Singapore Chef Association: Partnered with three rising chefs to craft a special Christmas menu;
              Launch of Sophie the Robotic Chef: The world’s first robotic noodle station, precision-engineered to serve local favourites.
2020 — Discovery Box and Lumiere Boxes: Innovative packaging formats for convenient, premium dining experiences.
2021 — Aurora Grand Patisserie: A reimagined catering format created during the pandemic, offering individual dessert deliveries as elegant gifting options.
     Gourmet Platters: Curated festive sharing platters, perfect for year-end celebrations and gatherings.
2022 — Christmas Wreath Splendour: An impressive 28″ festive centrepiece featuring cheeses, cold cuts, nuts, and other gourmet accompaniments.
2024 — Sandos: A new bento-style offering, combining a fusion of familiar and contemporary flavours with convenient, elegant packaging.
2025 — Revamped Aurora Dessert Bar: Modern twists on classics and a refreshed signature showcase.
             SG60-Inspired Canapés: A creative collection of modern bites that reinterpret familiar local flavours with an innovative twist.

These milestones reflect Orange Clove’s constant push to redefine the corporate catering landscape, blending creativity with precision to deliver memorable dining experiences for every occasion — from boardroom meetings to large-scale galas.

Beyond the food itself, Orange Clove is known for its imaginative event styling, with annual Christmas setups that create visually immersive experiences that engage both the eyes and palate.

“Being recognised as Singapore’s No. 1 corporate caterer and receiving the EXSA 2025 reflects the dedication of our team and partners. We have always believed that corporate catering can be as innovative, memorable, and service-oriented as dining in a top restaurant, and these awards validate our approach. We would also like to thank our customers for their unwavering support.” said Ms. TL Tan, Head of Sales at Orange Clove.

Orange Clove’s operational investments include a centralised kitchen with cold-chain logistics to maintain consistent food quality and safety, as well as sustainable, heat-retaining packaging that enhances the dining experience while supporting environmental initiatives.

As part of its ongoing sustainability commitment, the company continues to advance its Clove for Climate initiative — a long-term pledge to champion eco-friendly practices across all aspects of its operations. Orange Clove was Singapore’s first caterer to offer biodegradable ware, introducing bamboo and bagasse plates, bento boxes, and wooden cutlery as alternatives to single-use plastics. Its paper cups are coated with plant-based polylactic acid instead of plastic wax, while serviettes are made from Forest Stewardship Council (FSC)–certified paper.

Orange Clove also incorporates operational solutions to reduce waste and environmental impact. Reusable warmer bags are used for mini buffet orders, and traditional plastic bags have been replaced with custom-designed reusable tote bags to store self-heating trays, plates, and cutlery. The company also offers EcoPak water as a sustainable alternative to bottled mineral water and recycles used cooking oil into biodiesel — closing the loop in its pursuit of greener catering.

Through Clove for Climate, Orange Clove demonstrates that corporate catering can be both innovative and sustainable, setting a benchmark for environmentally responsible practices in Singapore’s food service industry.

Limited-Time Celebrations

To celebrate being named Singapore’s No. 1 Corporate Caterer, Orange Clove is offering special pricing on its signature Aurora Dessert Bar. First introduced as a pioneering concept in the catering scene, the Aurora Dessert Bar went beyond the traditional dessert table by combining oriental and western desserts in an upscale hotel–style showcase. Newly revamped, each piece is meticulously arranged and presented with exceptional attention to detail, reflecting Orange Clove’s commitment to innovation and elevated corporate dining experiences.

In addition, Orange Clove is offering complimentary upgrades on select canapé selections in recognition of its recent wins. Standouts include Chilli Crab Meat in Mini Charcoal Roll, Hainanese Pandan Kaya with Salted Butter in Charcoal Gougère, and Plant-based Meat Rendang with Coconut Gel, each a modern twist on familiar local flavours presented with elegance, reflecting the company’s commitment to culinary excellence.

Looking Ahead

Orange Clove continues to set the standard for corporate catering in Singapore, combining award-winning service, culinary innovation and collaboration, operational excellence and sustainable practices. As the company celebrates these recent accolades, including its recognition as Singapore’s No. 1 Corporate Caterer and the EXSA 2025 award, it remains committed to delivering memorable and customised dining experiences for corporate events of any scale.

About Orange Clove

Orange Clove was launched in 2008 to fill the market gap for corporate events that desire exquisite gastronomic fares. As the one-stop shop offering complete event management solutions from event conceptualisation to logistic setup and creative food catering, Orange Clove is the go-to caterer for corporate clients, especially multinational corporations.

As part of its brand extension strategy to capture a larger market share, Orange Clove also ventured into wedding planning, offering end-to-end solutions from venue sourcing to thematic setups and customised food menus for bridal couples. With an unwavering commitment to customer service, food quality and safety (first caterer to be awarded ISO 22000 for food safety management), it is no wonder that Orange Clove has bagged numerous awards and earned its pole position in Singapore.

Find out more about us here.

Source

Patent leadership reinforces company’s leading position in the global CBCT market

HWASEONG, South Korea, Feb. 27, 2026 /PRNewswire/ — Vatech (KOSDAQ: 043150), a global manufacturer of dental imaging systems, announced that cumulative patent data over the past 20 years demonstrate its technological leadership in dental diagnostic imaging.

Under the internationally recognized IPC classification A61B (medical diagnostics), Vatech ranked first in cumulative patent applications and granted patents among leading global dental diagnostic equipment manufacturers over the 2005–2025 period. The analysis reflects long-term innovation performance across the company’s principal growth phase.

Over the 20-year period, Vatech recorded 330 patent applications and 217 granted patents in dental diagnostic imaging technologies. Patent applications generally reflect forward-looking R&D direction, while granted patents indicate validated technical execution and secured intellectual property rights. Leadership across both measures underscores the scale and continuity of Vatech’s long-term innovation strategy.

This long-term accumulation of intellectual property aligns with Vatech’s evolution into a leading global provider of dental cone-beam computed tomography (CBCT) systems.

Innovation-Focused Patent Portfolio

Vatech’s patent portfolio is concentrated in platform-level innovations that have shaped the evolution of dental imaging systems. Core areas include:

• Low-dose imaging technologies
• Carbon nanotube (CNT)-based X-ray source systems

Approximately 19.6% of Vatech’s total granted patents are related to low-dose innovation technologies. These technologies are designed to reduce radiation exposure while maintaining diagnostic precision—an increasingly important clinical consideration in dental imaging.

By advancing both low-dose and high-resolution imaging technologies, Vatech has supported improved diagnostic environments and broader CBCT adoption across global markets.

Global Intellectual Property Strategy

Vatech has secured patent protection across major international markets, including the United States, Europe, China, and Japan, reflecting a coordinated intellectual property strategy aligned with its global commercial operations.

By consistently protecting core technologies across multiple jurisdictions, the company has established a robust intellectual property framework supporting cross-border commercialization and long-term product development.

Sustained R&D Strategy

Vatech emphasized that its patent leadership reflects sustained and consistent R&D investment over two decades rather than short-term expansion. Patent activity increased notably during the mid-2010s and continues to increase, particularly in next-generation imaging technologies.

The company remains focused on advancing precision imaging and low-dose innovation to support evolving global standards in dental diagnostics and to further strengthen its competitive position in the global CBCT market.

About Vatech

Vatech (www.vatech.com) is a global leader in dental imaging, specializing in advanced digital X-ray solutions with innovative low-dose technology. The company pioneered the world’s first 3-in-1 digital X-ray system and continues to lead the market with high-value 3D imaging products. Vatech is recognized for its cutting-edge technology and human-centered innovations. Vatech is a trusted brand among dental professionals worldwide, renowned for its commitment to innovation and excellence in dental diagnostics.

Source

Organised by The Hong Kong Chartered Governance Institute, in collaboration with The Hong Kong Jockey Club and funded by The Hong Kong Jockey Club Charities Trust, the Course delivers structured, accessible and internationally benchmarked training for those who lead and serve our sporting organisations.

HONG KONG, Feb. 27, 2026 /PRNewswire/ — The Hong Kong Chartered Governance Institute (“HKCGI”) today announced that enrolment is now open for the Jockey Club HKCGI Sports Governance Certification Course (“Course”), a professional certification course designed to elevate governance standards across Hong Kong’s National Sports Associations (“NSAs”). Enrolment is open to NSAs, with a limited number of places also available to HKCGI members and students. The Course is available on a complimentary basis.  

The Course arrives at a pivotal moment for Hong Kong sport. As the city’s athletes continue to distinguish themselves on the world stage, the organisations responsible for nurturing and supporting them must operate at the highest standards of transparency, accountability and professional management. Sound governance practices are fundamental to creating the stable, well-managed environments in which athletes can focus on their training and competition, and in which public confidence in sporting institutions can flourish.

The Sports Governance Certification Course addresses this imperative directly, providing NSAs with practical training in areas ranging from director duties and legal compliance to financial management, strategic planning and ethical leadership. The curriculum has been developed to ensure that participants can apply what they learn immediately within their organisations, strengthening governance from the boardroom through to daily operations.

The Course represents the centrepiece of the Jockey Club HKCGI Sports Governance Programme, made possible through a generous donation from The Hong Kong Jockey Club Charities Trust.

Speaking on the Programme, The Hong Kong Jockey Club (“Club”) stated that they are honoured to collaborate closely with Hong Kong NSAs, sharing the tools, resources and knowledge required to uphold the highest standards of governance. Through the Club’s Charities Trust’s donation, the Club hopes to empower NSAs to strengthen their governance.

The Programme also forms part of a broader initiative advanced by the Sports Governance and Integrity Alliance, a three-year partnership bringing together The Hong Kong Jockey Club, the Independent Commission Against Corruption, HKCGI and the Sports Federation & Olympic Committee of Hong Kong, China (“SF&OC”). This Alliance of four leading organisations reflects a shared commitment to strengthen governance and integrity across the sports sector.

“Strong governance is not a ‘nice-to-have’; it is the foundation upon which trusted, resilient and high-performing sport is built,” said Mr Tom SL Chau FCG HKFCG(PE), President of HKCGI. “Through this Course, we aim to support NSAs in strengthening their governance practices in ways that can be applied immediately and that will benefit Hong Kong sport for years to come.”

The Course comprises seven sequential modules totalling approximately 18 hours of online learning and allows participants to study at their own pace. Topics include director duties, legal and regulatory frameworks, strategic planning, financial management, stakeholder engagement, ethics and integrity and implementation of the SF&OC Code of Governance. Participants who successfully complete all modules and pass the final assessment will have their expertise validated with a Certificate of Completion and gain access to the Sports Governance Network, a dedicated platform connecting certified professionals with governance opportunities across Hong Kong’s sports sector.

Registration is open from 25 February to 12 May 2026 at www.sportsgovernance.org.hk

The Hong Kong Chartered Governance Institute

(Incorporated in Hong Kong with limited liability by guarantee)

The Hong Kong Chartered Governance Institute (HKCGI) is the sole accrediting body in Hong Kong and the Chinese mainland for the globally recognised Chartered Secretary and Chartered Governance Professional qualifications. Formerly known as The Hong Kong Institute of Chartered Secretaries (HKICS), HKCGI is the Hong Kong/China Division of The Chartered Governance Institute (CGI).

With a legacy of over 77 years, HKCGI has established itself as a trusted and reputable professional body in the region. Its influence extends to CGI’s global network of around 40,000 members, graduates and students. As one of CGI’s fastest-growing divisions, HKCGI’s community comprises about 10,000 members, graduates and students, with significant representation in listed companies and diverse governance roles across various industries.

Guided by the belief that governance leads to better decision-making and a better world, HKCGI is committed to advancing governance in commerce, industry and public affairs. It achieves this through education, thought leadership, advocacy and active engagement with its members and the broader community. As a recognised thought leader, HKCGI promotes the highest standards of governance while advocating for an inclusive approach that considers the interests of all stakeholders, and ensures that every voice is heard and valued.

Better Governance. Better Future.

For more information, please visit www.hkcgi.org.hk.

Source

SINGAPORE, Feb. 27, 2026 /PRNewswire/ — Trip.com has today unveiled the 3.3 Mega Sale for the school holidays and upcoming long weekends, happening from 3–6 March.

On top of the unmissable deals throughout the four days, you will enjoy even greater savings when you book flights for three or more people, or hotel stays of four nights or longer!

Four Days of Unmissable Deals with Trip.com’s 3.3 Mega Sale

From 3 to 6 March 2026, Trip.com will present a dizzying array of travel deals. From daily discount coupon drops at midnight, to all-in fare deals and flash sales for hotels, attractions and eSIMs, there are offers catering to all types of travellers.

Highlights of the Trip.com 3.3 Mega Sale include:

• Score up to S$60 OFF Flight and Hotel Bookings with Daily Midnight Coupon Drops, All-in-Fare Deals and Buy 1 Get 1 Free or Half-Price Deals: 

Get ready to snag the biggest travel discounts of the season from 12am on 3 March. With limited coupons up for grabs at midnight each day, only the fastest fingers will get to claim these unbeatable travel deals.

• Grab Unbeatable Flight Deals, including S$800 return flights to Auckland and London: 

Get your fingers ready to grab return flights to Auckland with Air New Zealand, or to London on Qatar Airways for an all-in price of just S$800^*!

DBS/ POSB cardholders can also enjoy up to 50% off flights to China at 12.00pm on 3 March.

• Double Your Adventures and Stay Connected:

Grab the person next to you and go on an adventure! Discover the most popular theme parks and local cultural gems alike with Buy 1 Get 1 Free or 50% Off deals, then share your photos online to show others what they’re missing with S$1 eSIMs^**.

Attractions include Shanghai Disneyland, Universal Studios Japan, Lotte World Adventure, Ocean Park Hong Kong, Warner Bros. Studio Tour Tokyo – The Making of Harry Potter, and Have Fun in Kansai Premium Pass, while S$1 eSIMs will be for destinations as diverse as China, Europe, Japan, and Thailand.

• Enjoy Greater Savings on Hotels with Special Promo Codes: 

Looking to book a popular hotel without breaking the bank? Don’t forget to grab promo codes to enjoy up to S$70 off stays for your next trip!

• More Deals and Discounts

The fun doesn’t end on 3 March. There are still many deals and discounts you can enjoy during the remainder of the campaign period from 4–6 March 2026, such as discounts of up to S$120 off flights for HSBC cardholders and 20% off flights and hotels for those heading to Thailand.

For first dibs on Trip.com deals and updates, join the Trip.com Singapore Telegram group at https://t.me/TriptalksSG.

Download Trip.com mobile app (available on the App Store or Google Play) to get the latest travel inspiration, recommendations and deals.

* Prices are before applicable services, taxes, and fees. All promotional offers are available on a first-come, first-served basis within the specified period and while stocks last. Terms and conditions apply.
** Data allowances and durations vary. Please refer to individual product listings for details.

About Trip.com

Trip.com is an international one-stop travel service provider, available in 24 languages across 39 countries and regions in 35 local currencies. Offering an extensive hotel and flight network of more than 1.5 million hotels and flights from over 640 airlines, along with over 300,000 attraction and tour products, Trip.com covers 3,400 airports in 220 countries and regions. Trip.com’s world-class 24/7 multilingual customer service helps to ‘create the best travel experience’ for its millions of customers worldwide. To book your next trip, visit Trip.com.

Source

SUZHOU, China, Feb. 27, 2026 /PRNewswire/ — Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and coupled with the side effects of BCG therapy itself, means that a substantial number of patients cannot access effective BCG treatment. Therefore, it is essential to seek better alternative therapies to BCG in order to meet clinical needs. Based on this, ImmVira Group is further expanding the clinical trial of its core oncolytic virus product, MVR-T3011—originally targeting BCG-unresponsive high-risk bladder cancer—to further include BCG-naïve bladder cancer patients.

On February 26, 2026, at the ASCO GU 2026 Conference in San Francisco, California, ImmVira Group announced preliminary positive results from its clinical trial evaluating MVR-T3011, an oncolytic virus, in BCG-naïve high-risk papillary Ta/T1 NMIBC patients for its leading oncolytic virus product, MVR-T3011, via intravesical administration. The data were presented in a poster at the Conference.

In the study involving 18 BCG-naïve high-risk papillary Ta/T1 NMIBC patients treated with intravesical MVR-T3011 at two dose levels: 2×10⁹ PFU (3 patients) and 1×10¹⁰ PFU (15 patients), preliminary data as of December 31, 2025, demonstrated encouraging efficacy and durability. Among the 14 evaluable patients, the 12-month recurrence-free-survival (RFS) rate was 100% (3/3) at the 2×10⁹ PFU dose level. At the 1×10¹⁰ PFU dose level, the 3-month RFS rate was 100% (11/11). The 6-month and 9-month RFS rates were 75% (3/4) and 66.7% (2/3), respectively, but these data are preliminary, given the small patient numbers reaching those timepoints.

Consistent with BCG-unresponsive clinical data, MVR-T3011 maintained a favorable safety profile in this study with most treatment-emergent adverse events (TEAEs) being at Grades 1 or 2. No treatment-related adverse events (TRAEs) were observed.

Bladder cancer ranks as the ninth most prevalent cancer worldwide^[1], with approximately 75% of cases classified as NMIBC. While Bacillus Calmette-Guerin (BCG) remains the current SOC for high-risk NMIBC, global shortages have limited its availability. As a result, oncolytic immunotherapy, which offers enhanced immune activation and potential durability, is emerging as a promising alternative.

“We are highly encouraged by the preliminary efficacy and safety data from the study,” said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. “MVR-T3011 shows its potential to serve as a reliable and widely accessible alternative to BCG, ultimately benefiting patients worldwide.”

Source:
1. GLOBOCAN 2022: Bladder cancer 9th most common worldwide

About MVR-T3011

MVR-T3011, represents a breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary “3-in-1” design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability and feasibility across multiple routes of administration including intratumoral, intracavitary and intravenous administrations.

About ImmVira

ImmVira is a clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. We have strategically designed, self-discovered, and built a risk-balanced product portfolio that comprised two oncolytic immunotherapy candidates for solid tumors and five engineered exosome assets poised for clinical application or direct commercialization. Driven by our vision to become a global leader in the full spectrum of bladder cancer treatment development and unlock the therapeutical potential of oncolytic immunotherapy in head and neck squamous cell carcinoma (HNSCC), we have adopted a rationalized, adaptive approach to advance oncolytic immunotherapy candidates with high clinical potential globally. In parallel, leveraging our deep expertise in biological engineering, we have pioneered development of engineered exosome candidates targeting chronic, hard-to-treat diseases as well as age-related conditions. These selected engineered exosome assets are being accelerated through differentiated regulatory pathways to enable expedited commercialization and generate sustainable cash flows that will fuel our broader drug development efforts.

Source